Reuters logo
BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
November 21, 2017 / 7:36 AM / a month ago

BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd

* Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co

* Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey

Source text in Japanese:goo.gl/nQ93sZ

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below